Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/β- catenin signaling in prostate cancer cells

Monica Ciarlo, Roberto Benelli, Ottavia Barbieri, Simona Minghelli, Paola Barboro, Cecilia Balbi, Nicoletta Ferrari

Research output: Contribution to journalArticle

Abstract

Current diagnostic tools cannot predict clinical failure and androgen-independent disease progression for patients with prostate cancer (PC). The survival signaling pathways of prostate cells play a central role in the progression of tumors to a neuroendocrine (NE) phenotype. NE cells demonstrate attributes that suggest that they are an integral part of the signaling cascade leading to castration-resistant PC. In this study, making use of in vitro neuroendocrine differentiation (NED) of human LNCaP and mouse TRAMP-C2 cells after androgen withdrawal, and of the transgenic adenocarcinoma of mouse prostate (TRAMP) model, we characterized a sequence of molecular events leading to NED and identified a number of markers that could be detectable by routine analyses not only in castration resistant PC but also in hormone naïve PC at the time of initial diagnosis. We found that NED associates with AKT activation that in turn regulates heterogeneous nuclear ribonucleoprotein K (hnRNP K), androgen receptor (AR) and β-catenin levels. Addition of molecules targeting membrane-bound receptors and protein kinases blocks NE differentiation in LNCaP and TRAMP-C2 cells. The extent of AKT phosphorylation and hnRNP K, AR and β-catenin levels may have a potential value as prognostic indicators discriminating between androgen-responsive and unresponsive cells and could be used as molecular targets to monitor the anti-tumor action of new therapeutic protocols based on antireceptor agents and/or neuroendocrine hormone antagonists.

Original languageEnglish
Pages (from-to)582-590
Number of pages9
JournalInternational Journal of Cancer
Volume131
Issue number3
DOIs
Publication statusPublished - Aug 1 2012

Fingerprint

Catenins
Androgen Receptors
Prostate
Prostatic Neoplasms
Heterogeneous-Nuclear Ribonucleoprotein K
Transgenic Mice
Androgens
Adenocarcinoma
Castration
Hormone Antagonists
Neuroendocrine Cells
Protein Kinases
Disease Progression
Neoplasms
Phosphorylation
Hormones
Phenotype
Membranes
Survival
Therapeutics

Keywords

  • β-catenin
  • AKT
  • androgen receptor
  • heterogeneous nuclear ribonucleoprotein K
  • neuroendocrine differentiation
  • prostate cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/β- catenin signaling in prostate cancer cells. / Ciarlo, Monica; Benelli, Roberto; Barbieri, Ottavia; Minghelli, Simona; Barboro, Paola; Balbi, Cecilia; Ferrari, Nicoletta.

In: International Journal of Cancer, Vol. 131, No. 3, 01.08.2012, p. 582-590.

Research output: Contribution to journalArticle

@article{db18922aa8f442a1b46795ffc27fd990,
title = "Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/β- catenin signaling in prostate cancer cells",
abstract = "Current diagnostic tools cannot predict clinical failure and androgen-independent disease progression for patients with prostate cancer (PC). The survival signaling pathways of prostate cells play a central role in the progression of tumors to a neuroendocrine (NE) phenotype. NE cells demonstrate attributes that suggest that they are an integral part of the signaling cascade leading to castration-resistant PC. In this study, making use of in vitro neuroendocrine differentiation (NED) of human LNCaP and mouse TRAMP-C2 cells after androgen withdrawal, and of the transgenic adenocarcinoma of mouse prostate (TRAMP) model, we characterized a sequence of molecular events leading to NED and identified a number of markers that could be detectable by routine analyses not only in castration resistant PC but also in hormone na{\"i}ve PC at the time of initial diagnosis. We found that NED associates with AKT activation that in turn regulates heterogeneous nuclear ribonucleoprotein K (hnRNP K), androgen receptor (AR) and β-catenin levels. Addition of molecules targeting membrane-bound receptors and protein kinases blocks NE differentiation in LNCaP and TRAMP-C2 cells. The extent of AKT phosphorylation and hnRNP K, AR and β-catenin levels may have a potential value as prognostic indicators discriminating between androgen-responsive and unresponsive cells and could be used as molecular targets to monitor the anti-tumor action of new therapeutic protocols based on antireceptor agents and/or neuroendocrine hormone antagonists.",
keywords = "β-catenin, AKT, androgen receptor, heterogeneous nuclear ribonucleoprotein K, neuroendocrine differentiation, prostate cancer",
author = "Monica Ciarlo and Roberto Benelli and Ottavia Barbieri and Simona Minghelli and Paola Barboro and Cecilia Balbi and Nicoletta Ferrari",
year = "2012",
month = "8",
day = "1",
doi = "10.1002/ijc.26402",
language = "English",
volume = "131",
pages = "582--590",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/β- catenin signaling in prostate cancer cells

AU - Ciarlo, Monica

AU - Benelli, Roberto

AU - Barbieri, Ottavia

AU - Minghelli, Simona

AU - Barboro, Paola

AU - Balbi, Cecilia

AU - Ferrari, Nicoletta

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Current diagnostic tools cannot predict clinical failure and androgen-independent disease progression for patients with prostate cancer (PC). The survival signaling pathways of prostate cells play a central role in the progression of tumors to a neuroendocrine (NE) phenotype. NE cells demonstrate attributes that suggest that they are an integral part of the signaling cascade leading to castration-resistant PC. In this study, making use of in vitro neuroendocrine differentiation (NED) of human LNCaP and mouse TRAMP-C2 cells after androgen withdrawal, and of the transgenic adenocarcinoma of mouse prostate (TRAMP) model, we characterized a sequence of molecular events leading to NED and identified a number of markers that could be detectable by routine analyses not only in castration resistant PC but also in hormone naïve PC at the time of initial diagnosis. We found that NED associates with AKT activation that in turn regulates heterogeneous nuclear ribonucleoprotein K (hnRNP K), androgen receptor (AR) and β-catenin levels. Addition of molecules targeting membrane-bound receptors and protein kinases blocks NE differentiation in LNCaP and TRAMP-C2 cells. The extent of AKT phosphorylation and hnRNP K, AR and β-catenin levels may have a potential value as prognostic indicators discriminating between androgen-responsive and unresponsive cells and could be used as molecular targets to monitor the anti-tumor action of new therapeutic protocols based on antireceptor agents and/or neuroendocrine hormone antagonists.

AB - Current diagnostic tools cannot predict clinical failure and androgen-independent disease progression for patients with prostate cancer (PC). The survival signaling pathways of prostate cells play a central role in the progression of tumors to a neuroendocrine (NE) phenotype. NE cells demonstrate attributes that suggest that they are an integral part of the signaling cascade leading to castration-resistant PC. In this study, making use of in vitro neuroendocrine differentiation (NED) of human LNCaP and mouse TRAMP-C2 cells after androgen withdrawal, and of the transgenic adenocarcinoma of mouse prostate (TRAMP) model, we characterized a sequence of molecular events leading to NED and identified a number of markers that could be detectable by routine analyses not only in castration resistant PC but also in hormone naïve PC at the time of initial diagnosis. We found that NED associates with AKT activation that in turn regulates heterogeneous nuclear ribonucleoprotein K (hnRNP K), androgen receptor (AR) and β-catenin levels. Addition of molecules targeting membrane-bound receptors and protein kinases blocks NE differentiation in LNCaP and TRAMP-C2 cells. The extent of AKT phosphorylation and hnRNP K, AR and β-catenin levels may have a potential value as prognostic indicators discriminating between androgen-responsive and unresponsive cells and could be used as molecular targets to monitor the anti-tumor action of new therapeutic protocols based on antireceptor agents and/or neuroendocrine hormone antagonists.

KW - β-catenin

KW - AKT

KW - androgen receptor

KW - heterogeneous nuclear ribonucleoprotein K

KW - neuroendocrine differentiation

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84861576558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861576558&partnerID=8YFLogxK

U2 - 10.1002/ijc.26402

DO - 10.1002/ijc.26402

M3 - Article

C2 - 22015967

AN - SCOPUS:84861576558

VL - 131

SP - 582

EP - 590

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -